Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
J Clin Oncol
; 27(27): 4522-9, 2009 Sep 20.
Article
em En
| MEDLINE
| ID: mdl-19687336
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Polietilenoglicóis
/
Neoplasias da Mama
/
Doxorrubicina
/
Taxoides
/
Antineoplásicos
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article